Title : Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.

Pub. Date : 2010 Feb 10

PMID : 20038723






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 EGFR mutation-positive patients had longer progression-free survival (PFS; hazard ratio [HR], 0.16; 95% CI, 0.05 to 0.49; P = .001) and higher objective response rate (ORR; 42.1% v 21.1%; P = .04), and patients with high EGFR copy number had higher ORR (13.0% v 7.4%; P = .04) with gefitinib versus docetaxel. Docetaxel epidermal growth factor receptor Homo sapiens
2 For secondary end points of PFS and ORR, some advantages for gefitinib over docetaxel were seen in EGFR mutation-positive and high EGFR copy number patients. Docetaxel epidermal growth factor receptor Homo sapiens
3 For secondary end points of PFS and ORR, some advantages for gefitinib over docetaxel were seen in EGFR mutation-positive and high EGFR copy number patients. Docetaxel epidermal growth factor receptor Homo sapiens